Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer, Neurodegenerative and Metabolic diseases. The Arrien Pharmaceuticals successfully applied and applying its proprietary platform FIELDS technology and discovered a pipeline of uniquely positioned pre-clinical stage programs for future treatment of Rheumatoid Arthritis (RA), Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, Lung and GBM), Parkinson's, and Diabesity Diseases.
Arrien Pharmaceuticals FIELDS technology is a Fragment-Field Drug Design (FFDD) typically involves empirical and structural data input assisting our Medicinal Chemists in early phase of lead-to-drug-lead design process. Arrien Pharmaceuticals cost-competent approach rapidly aid our scientific team in selecting pre-clinical candidate ready compounds.
Arrien Pharmaceuticals advanced ARN-4079, ARN-6039, ARN-3236 and ORS-1104 programs into IND enabling studies
Arrien Pharmaceuticals competitive and unique drug discovery approaches coupled with experienced scientific and management team with expertise in multidisciplinary areas of medicinal, biological and Clinical Sciences has been the key to company's technology and success since its incorporation in 2011.